Corpus Intelligence IC Memo — WIREGRASS MEDICAL CENTER 2026-04-26 09:05 UTC
IC Memo — WIREGRASS MEDICAL CENTER
Investment Committee Memorandum | AL | 33 beds | Grade C | EBITDA uplift $1.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

WIREGRASS MEDICAL CENTER

CCN 010062 | GENEVA, AL | 33 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

WIREGRASS MEDICAL CENTER is a 33-bed under-performing / distressed in GENEVA, AL with $21.0M in net patient revenue and a -14.2% operating margin. The hospital serves a payer mix of 33.4% Medicare, 20.9% Medicaid, and 45.7% commercial.

Thesis: Turnaround. Our ML models identify $1.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -14.2% to -6.9% (+736bps).

Net Revenue HCRIS$21.0M
Current EBITDA COMPUTED$-3.0M
Operating Margin COMPUTED-14.2%
Occupancy HCRIS32.4%
Revenue / Bed COMPUTED$637K
Net-to-Gross HCRIS55.5%
Distress Probability ML60.0%

2. Market Context & Competitive Position

115
AL Hospitals
-8.5%
State Median Margin
57
Comparable Hospitals

AL has 115 Medicare-certified hospitals with a median operating margin of -8.5%. The target's margin of -14.2% places it below the state median. Among 57 size-comparable peers (16-66 beds), the median margin is -16.5%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (16-66), prioritizing same-state peers. 57 hospitals in the comp set.

HospitalStateBedsRevenueMargin
WIREGRASS MEDICAL CENTER (Target)AL33$21.0M-14.2%
ATHENS LIMESTONEAL66$88.9M-20.9%
RUSSELL MEDICAL CENTERAL45$75.3M-14.8%
JACK HUGHSTON MEMORIAL HOSPITAAL47$75.2M6.5%
EASTPOINTE HOSPITALAL66$56.6M-50.0%
NORTH BALDWIN INFIRMARYAL35$55.3M-3.3%
PRATTVILLE BAPTIST HOSPITALAL55$53.5M-16.2%
HIGHLANDS MEDICAL CENTERAL45$45.9M-30.2%
ST. VINCENTS ST. CLAIRAL40$40.8M8.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$441K+210bp18mo
Cost to Collect4.5%2.5%$420K+200bp12mo
Denial Rate Reduction12.0%6.5%$416K+198bp12mo
A/R Days Reduction5200.0%3800.0%$256K+122bp9mo
Clean Claim Rate88.0%96.0%$13K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$441K
Cost to Collect
$420K
Denial Rate Reduction
$416K
A/R Days Reduction
$256K
Clean Claim Rate
$13K
Total EBITDA Uplift$1.5M
Current EBITDA$-3.0M
+ RCM Uplift+$1.5M
Pro Forma EBITDA$-1.4M
Current Margin-14.2%
Pro Forma Margin-6.9%
WC Released (1x)$806K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-4.6M$-4.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-4.6M$-6.2M0.00x-100.0%
Bull Case9.0x11.0x$-4.1M$-2.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-4.1M$-4.0M0.00x-100.0%
Bear Case11.0x10.0x$-5.1M$-10.5M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-5.1M$-13.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 32.4%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 60.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 57 hospitals with 16-66 beds
  • Same-state prioritization (n=58)
  • Comp margins: P25=-29.4% / P50=-16.5% / P75=-2.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.